Delivery Order SPE2DB22D1017-SPE2DB25FF3UZ

Award Date 1/23/25
Potential Completion Date 1/24/25
Potential Value $6.8K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the provision of ABIRATERONE ACETATE 250 MG TAB 120S. The firm-fixed-price Delivery Order is valued at $16,991.13 and has an ultimate completion date of January 27, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,679.26 firm fixed-price delivery order is for the supply of 4,565,672,909 units of abiraterone acetate 250 mg tablets. The award has a completion date of September 5, 2024 and was made on September 4, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award, valued at $1,481.38, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The award is for the delivery of 4,566,734,838 units of Abiraterone Acetate 500 mg tablets. This is a Firm Fixed Price delivery order with a completion date of December 17, 2024. The contract is not designated with a set-aside requirement, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery...
This is a federal contract award issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $6,225.33 firm-fixed-price delivery order is for the supply of 4,566,263,297 units of the drug Abiraterone Acetate 500 mg tablets. The contract has an ultimate completion date of October 30, 2024 and was awarded on October 29, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,262.07 firm fixed-price delivery order is for the supply of 4,566,692,987 units of Abiraterone Acetate 500 mg tablets. The contract has an ultimate completion date of December 12, 2024 and does not utilize any set-aside requirements, indicating open competition. AmerisourceBergen holds a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,313.32, is for the supply of 4,566,561,596 units of abiraterone acetate 250 mg tablets. The contract is a firm fixed-price delivery order with a completion date of November 29, 2024. This contract is not designated as a set-aside. AmerisourceBergen holds a...
This federal contract award, valued at $6,313.33, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the supply of 4,566,932,510 units of Abiraterone Acetate 500 mg tablets, with an ultimate completion date of January 15, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,396.87 Firm Fixed Price delivery order is for the supply of 4,566,832,579 units of Abiraterone Acetate 500 mg tablets. The award is not designated as a set-aside contract. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $26,185.49 firm fixed-price delivery order (Contract #SPE2DX15D1053|SPE2DX25F6EQG) is for the supply of 4,566,661,237 units of Abiraterone Acetate 250 mg tablets. This award is part of AmerisourceBergen's larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award is to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distribution company, to provide 4,564,755,143 units of Abiraterone Acetate 500 mg tablets to the Defense Logistics Agency (DLA) Troop Support Medical. The contract is a Delivery Order under Amerisourcebergen's existing Indefinite Delivery Contract (IDC) with the DLA, valued at up to $999,999,999.00 through December 31, 2025. This single-award IDC serves as the primary vehicle for...
  • SPE2DB22D1017
    Indefinite Delivery Contract
  • SPE2DB22D1017-SPE2DB25FF3UZ
    Delivery Order

This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Abiraterone Acetate 500 mg tablets. The contract, valued at $6,804.99, is a Firm Fixed Price Delivery Order with a completion date of January 24, 2025. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as the primary vehicle for providing a wide range of pharmaceutical products and medical supplies to support military healthcare programs globally. This award does not have a set-aside designation, indicating open competition.

Generated 4/24/25, 9:46 AM